logo
ABBV_logo
AbbVie has a rich legacy spanning more than two decades where we have consistently worked to deliver new insights and innovation in rheumatology," said Celine Goldberger, M.D., Ph.D., vice president, head of U.S. medical affairs, AbbVie. "Data being presented at this year's ACR meeting further reflect AbbVie's commitment to advancing our portfolio of medicine to help more people living with chronic and debilitating conditions achieve meaningful disease control

AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022

AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and SKYRIZI® (risankizumab) for psoriasis and psoriatic arthritis at the American College of Rheumatology's annual meeting (ACR Convergence 2022) taking place November 10-14 in Philadelphia, PA, as well as virtually

By AP News
Published - Nov 08, 2022, 04:21 PM ET
Last Updated - Jul 26, 2024, 12:44 AM EDT
  • Thirty-six abstracts underscore AbbVie's commitment to advancing research to help more people living with rheumatic diseases
  • Additional analysis of long-term safety data for RINVOQ® (upadacitinib) and SKYRIZI® (risankizumab)
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024